Sequoia’s Roelof Botha: Why Venture Capital is Broken & How Great Companies Are Built

Summary

Live on stage at an All-In event, Sequoia's Roelof Botha discusses the Scout program (now a 26x fund), why the venture industry is structurally over-capitalized ($150-200 billion a year would need roughly 40 Figma-sized exits annually, making venture a 'return-free risk'), and why Sequoia separated from its China business as company formation there collapsed under regulatory uncertainty. He explains Sequoia's unanimous investment decisions, its private-partnership structure and the Sequoia Capital Fund, which keeps post-IPO shares of compounders instead of distributing them and has added $6.7 billion in gains. The conversation closes with lessons from Doug Leone and Michael Moritz and Sequoia's limited life-sciences push, where Natera grew from a $1 million seed into a roughly $22 billion company while the firm concedes it lacks biotech expertise.

• Sequoia's Scout program, conceived in 2010, is now a 26x fund; Venture XII and XIII were both north of 20x.
• Botha calls venture a 'return-free risk': $150-200B deployed yearly needs over $1T of annual exit value, but only about 20 companies per decade exit above $1B.
• Sequoia separated its China business (now HongShan) after the integration premise failed; Chinese company formation fell from 51,000 in 2018 to 1,200 in 2023.
• Sequoia keeps its seed, venture and growth funds no larger than 5-7 years ago, decides investments by unanimous consensus and is structured as a private partnership in perpetuity.
• The Sequoia Capital Fund (2022) holds post-IPO shares of likely compounders instead of distributing them, citing Palo Alto Networks, ServiceNow, HubSpot and MongoDB as 10x public-market compounders; $6.7B in added gains so far.
• Companies Sequoia backed privately now account for over 30% of NASDAQ value; founder-led firms keep reinventing themselves, e.g. Cash App at Square/Block.
• In life sciences, Natera grew from a $1M seed in 2007 to a roughly $22B market cap as the leader in prenatal, oncology-recurrence and transplant-rejection testing; Sequoia also backed BridgeBio but admits it lacks MD/PhD expertise.
• Botha warns that AI regulatory uncertainty in the US could deter founders the way policy uncertainty did in China.